# Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients

> **NCT00338039** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 69 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT00338039
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2013-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338039, "Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00338039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*